The frequency of KRAS mutations in non‐small cell lung cancer (NSCLC) cases has been reported to be 20%–30%, while in invasive mucinous adenocarcinoma cases the frequency is 50%–70%.10 This evidence concerns the gene KRAS and colon mucinous adenocarcinoma.